The first stock that I chose was BIIB, which didn’t perform very well. For about a month that I had it, from February 4th to March 2nd, the stock only rose a tiny 1,05%, from $270 to $273, which forced me to change my tactic from buying expensive stocks to buying cheap stocks. The reason for the poor performance was because the competition in the healthcare industry was extremely high. As a result, Biogen Inc. couldn’t draw much customers. Also, Biogen Inc. had recently cut off some health and drug development programs, as well as some staffs because of the lack of
The first stock that I chose was BIIB, which didn’t perform very well. For about a month that I had it, from February 4th to March 2nd, the stock only rose a tiny 1,05%, from $270 to $273, which forced me to change my tactic from buying expensive stocks to buying cheap stocks. The reason for the poor performance was because the competition in the healthcare industry was extremely high. As a result, Biogen Inc. couldn’t draw much customers. Also, Biogen Inc. had recently cut off some health and drug development programs, as well as some staffs because of the lack of